Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$4.03 - $6.5 $3,776 - $6,090
-937 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$10.6 - $13.12 $25,811 - $31,947
-2,435 Reduced 72.21%
937 $11,000
Q4 2018

Feb 13, 2019

SELL
$8.47 - $14.71 $635 - $1,103
-75 Reduced 2.18%
3,372 $31,000
Q3 2018

Nov 13, 2018

SELL
$13.7 - $17.12 $1,274 - $1,592
-93 Reduced 2.63%
3,447 $50,000
Q2 2018

Aug 13, 2018

SELL
$14.63 - $19.19 $438 - $575
-30 Reduced 0.84%
3,540 $57,000
Q1 2018

May 14, 2018

BUY
$16.06 - $25.35 $39,636 - $62,563
2,468 Added 223.96%
3,570 $58,000
Q4 2017

Feb 09, 2018

SELL
$10.51 - $17.22 $1,229 - $2,014
-117 Reduced 9.6%
1,102 $18,000
Q3 2017

Nov 14, 2017

BUY
$10.14 - $14.85 $12,360 - $18,102
1,219
1,219 $54,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $16.3M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Itau Unibanco Holding S.A. Portfolio

Follow Itau Unibanco Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Itau Unibanco Holding S.A. with notifications on news.